Accès gratuit
Numéro
Med Sci (Paris)
Volume 27, Numéro 12, Décembre 2011
Page(s) 1106 - 1111
Section M/S Revues
DOI http://dx.doi.org/10.1051/medsci/20112712017
Publié en ligne 23 décembre 2011
  1. Sablina AA, Hector M, Colpaert N, Hahn WC. Identification of PP2A complexes and pathways involved in cell transformation. Cancer Res 2010 ; 70 : 10474–10484. [CrossRef] [PubMed]
  2. Janssens V, Jozef Goris J, Van Hoof C. PP2A: the expected tumor suppressor. Curr Opin Genet Dev 2005 ; 15 : 34–41. [NASA ADS] [CrossRef] [MathSciNet] [PubMed]
  3. Eichhorn PJ, Creyghton MP, Bernards R. Protein phosphatase 2A regulatory subunits and cancer. Biochim Biophys Acta 2009 ; 1795 : 1–15. [PubMed]
  4. Shtrichman R, Sharf R, Barr H, et al. Induction of apoptosis by adenovirus E4orf4 protein is specific to transformed cells and requires an interaction with protein phosphatase 2A. Proc. Natl Acad Sci USA 1999 ; 96 : 10080–10085. [CrossRef]
  5. Rundell K, Major EO, Lanpert M. Association of cellular 56000- and 32000-molecular-weight protein with BK virus and polyoma virus t-antigens. J Virol 1981 ; 37 : 1090–1093. [PubMed]
  6. Garibal J, Hollville E, Bell AI, et al. Truncated form of the Epstein-Barr virus protein EBNA-LP protects against caspase-dependent apoptosis by inhibiting protein phosphatase 2A. J Virol 2007 ; 81 : 598–607. [CrossRef]
  7. Sariyer IK, Khalili K, Safak M. Dephosphorylation of JC virus agnoprotein by protein phosphatase 2A: inhibition by small t antigen. Virology 2008 ; 375 : 64–79. [CrossRef]
  8. Bollag B, Hofstetter CA, Reviriego-Mendoza MM, Frisque RJ. JC virus small t antigen binds phosphatase PP2A and Rb family proteins, is required for efficient viral DNA replication activity. PLoS One 2010 ; 5 : e10606. [CrossRef] [PubMed]
  9. Georgopoulou U, Tsitoura P, Kalamvoki M, Mavromara P. The protein phosphatase 2A represents a novel cellular target for hepatitis C virus NS5A protein. Biochimie 2006 ; 88 : 651–662. [CrossRef] [PubMed]
  10. Godet AN, Guergnon J, Croset A, et al. PP2A1 binding, cell transducing and apoptotic properties of Vpr77–92 : a new functional domain of HIV-1 Vpr proteins. PLoS One 2010 ; 5 : e13760. [CrossRef] [PubMed]
  11. Pim D, Massimi P, Dilworth SM, Banks L. Activation of the protein kinase B pathway by the HPV-16 E7 oncoprotein occurs through a mechanism involving interaction with PP2A. Oncogene 2005 ; 24 : 830–838.
  12. Kwun HJ, Guastafierro A, Shuda M, et al. The minimum replication origin of Merkel cell polyomavirus has a unique large T-antigen loading architecture and requires small T-antigen expression for optimal replication. J Virol 2009 ; 83 : 12118–12128. [CrossRef] [PubMed]
  13. Benjamin TL. Polyoma virus: old findings and new challenges. Virology 2001 ; 289 : 167–173. [CrossRef] [PubMed]
  14. Dilworth SM. Polyoma virus middle T antigen and its role in identifying cancer-related molecules. Nat Rev Cancer 2002 ; 2 : 951–956. [CrossRef] [PubMed]
  15. Hong S, Wang LC, Gao X, et al. Heptad repeats regulate protein phosphatase 2a recruitment to I-kappaB kinase gamma/NF-kappaB essential modulator and are targeted by human T-lymphotropic virus type 1 tax. J Biol Chem 2007 ; 282 : 12119–12126. [CrossRef] [PubMed]
  16. Hunt TA, Urbanowski MD, Kakani K, et al. Interactions between the West Nile virus capsid protein and the host cell-encoded phosphatase inhibitor, I2PP2A. Cell Microbiol 2007 ; 9 : 2756–2766. [CrossRef] [PubMed]
  17. Guénin S, Schwartz L, Morvan D, et al. PP2A activity is controlled by methylation and regulates oncoprotein expression in melanoma cells: a mechanism which participates in growth inhibition induced by chloroethylnitrosourea treatment. Int J Oncol 2008 ; 32 : 49–57. [PubMed]
  18. Junttila MR, Puustinen P, Niemela M, et al. CIP2A inhibits PP2A in human malignancies. Cell 2007 ; 130 : 51–62. [CrossRef] [PubMed]
  19. Come C, Laine A, Chanrion M, et al. CIP2A is associated with human breast cancer aggressivity. J Clin Cancer Res 2009 ; 15 : 5092–5100. [CrossRef]
  20. Zhao D, Liu Z, Ding J, et al. Helicobacter pylori CagA upregulation of CIP2A is dependent on the Src and MEK/ERKpathways. J Med Microbiol 2010 ; 59 : 259–265. [CrossRef] [PubMed]
  21. Neviani P, Santhanam R, Trotta R, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 2005 ; 8 : 355–368. [CrossRef] [PubMed]
  22. Chen LP, Lai YD, Li DC, et al. α4 is highly expressed in carcinogen-transformed human cells and primary human cancers. Oncogene 2011 ; 20 : 2943–2953. [CrossRef]
  23. Marcellus RC, Chan H, Paquette D, et al. Induction of p53-independent apoptosis by the adenovirus E4orf4 protein requires binding to the Balpha subunit of protein phosphatase 2A. J Virol 2000 ; 74 : 7869–7887. [CrossRef] [PubMed]
  24. Robert A, Miron MJ, Champagne C, et al. Distinct cell death pathways triggered by the adenovirus early region 4 ORF 4 protein. J Cell Biol 2002 ; 158 : 519–528. [CrossRef] [PubMed]
  25. Mitrus I, Missol-Kolka E, Plucienniczak A, Szala S. Tumour therapy with genes encoding apoptin and E4orf4. Anticancer Res 2005 ; 25 : 1087–1090. [PubMed]
  26. Neviani P, Santhanam R, Oaks JJ, et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest 2007 ; 117 : 2408–2421. [CrossRef] [PubMed]
  27. Matsuoka Y, Nagahara Y, Ikekita M, Shinomiya T. A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells. Br J Pharmacol 2003 ; 138 : 1303–1312. [CrossRef] [PubMed]
  28. Guergnon J, Dessauge F, Dominguez V, et al. Use of penetrating peptides interacting with PP1/PP2A proteins as a general approach for a drug phosphatase technology. Mol Pharmacol 2006 ; 69 : 1115–1124. [CrossRef] [PubMed]
  29. Godet AN, Guergnon J, Maire V, et al. The combinatorial PP1-binding consensus motif (R/K)x (0, 1)V/IxFxx(R/K)x(R/K) is a new apoptotic signature. PloS One 2010 ; 5 : e9981. [CrossRef] [PubMed]